Introduction

M
any countries worldwide have a national or regional policy of antenatal screening of HIV. In 2005, a structured questionnaire among 25 EU Member States showed that 18 countries had a national screening policy. 1 The value of antenatal HIV screening is determined by several factors, like HIV prevalence, uptake of antenatal HIV testing, time of testing, availability of strategies aimed at the prevention of mother-to-child-transmission and HIVseroconversions in pregnant or lactating women after negative antenatal testing. In the highly active antiretroviral treatment (HAART) era, prevention of mother-to-child-transmission has become very effective. For instance, in the AMRO study, MTCT was 0% in 143 mother-child pairs between December 1997 and July 2003. 2 Side effects on the other hand were low for the pregnant women who started HAART in pregnancy for prevention of mother-to-child-transmission. Other studies have shown similar results in countries where HAART is available. [3] [4] [5] Although the prevalence of HIV is relatively low in Western European countries, it is rising gradually. In the area of Amsterdam, the prevalence of HIV in pregnant women was tested in 1990-91 and again from 2002 onwards.
The prevalence appeared to have increased from 0.1 to 0.26%. 6 In the UK, the prevalence of HIV in women giving birth in England and Scotland increased similarly from 0.09% in 2000 to 0.21% in 2007.
objected to having the test. In Amsterdam, non-selective screening instead of selective screening of HIV in pregnancy was implemented in 2002 according to the opt-in principle, i.e. they were only tested after consent. 8 The opt-out principle in first trimester screening in Amsterdam was implemented in 2003, during the year that the Dutch government decided to extend this strategy to the whole nation per 1 January 2004. 8, 9 The decision to implement the opt-out principle was also based upon the Amsterdam data. The data showed a decrease in test refusals from 13.6% using the opt-in principle to 1.4% at the end of the first year using the opt-out principle. These results are comparable to international studies. 10, 11 In the present study, we examine the performance of the two HIV screening strategies in pregnancy in terms of detection of new cases of HIV and vertical transmission.
Methods
Study population
Patients were participants in the AIDS Therapy Evaluation Project (ATHENA), the national observational HIV cohort in the Netherlands. ATHENA has been described in detail elsewhere. 12 Briefly, this cohort includes HIV-infected patients followed in one of the 25 designated HIV treatment centres. By January 2008, data of 14 536 HIV-infected patients were included in ATHENA.
For the present study, all HIV-infected pregnant women (delivery >16 weeks) registered in the ATHENA observational cohort were included. All pregnancies where HIV was diagnosed during the pregnancy and all first pregnancies which occurred after an HIV diagnosis outside of pregnancy were selected for these analyses. We chose to include each woman once in the analyses. By including more pregnancies after the HIV diagnosis, we would have included women with a previously known HIV infection multiple times. The study period lasted from 1 January 2000 to 1 January 2008. In this period, the prophylactic treatment of pregnant women to reduce vertical transmission of HIV hardly changed: HAART continued or started usually between 24-28 weeks and an elective caesarean section in case of HAART failure the latest 39 weeks, followed by 4 weeks PEP for the newborn and bottle feeding. However nationwide, the screening policy changed from targeted-selective-screening aimed at pregnant women deemed to be at increased risk of HIV after informed consent (opt-in principle) to general-non-selectivescreening by which they were tested for HIV unless they objected to having the test (opt-out principle). Virtually all pregnant women known with HIV in the Netherlands have been included in the ATHENA observational cohort. However, the pregnancy-related data collection (such as outcome of the pregnancy, birth or induced/spontaneous abortion and the mode of delivery) was not yet complete for 2007 for all hospitals at the time of our analysis. For the present study, we included only data from those pregnant women for whom the collection of additional data was complete. In the ATHENA observational cohort also, all HIV-infected children are registered. These children are followed in four national referral centres. In addition to the routine data collection within ATHENA, for the present analysis of the effectiveness of screening for prevention of mother-to-child-transmission in a concurrent study, all referral centres were asked about all HIV-infected children that came under their surveillance/treatment between 1 January 2004 and 1 May 2009 in order to find unregistered HIV-infected children.
Data collection
Data were collected on demographics (age and region of origin), date of HIV-diagnosis, most likely transmission route, CD4
+ cell count at diagnosis and before delivery, initiation of combined anti-retroviral therapy, HIV-RNA load before delivery and length of pregnancy. Data of pregnant women and their children in this registry are also not linked. According to Dutch law, no informed consent has to be given for such anonymous clinical data.
Statistics
Logistic regression models were used to determine predictive factors for a diagnosis of a previously unknown HIV status during pregnancy. Factors that were included in the multivariate model were region of origin, age at the start of pregnancy, known HIV status, start of HAART, year of HIV diagnosis, hospital and CD4 + cells and viral load at delivery. Year of HIV diagnosis was categorized according to the implementation of the opt-out principle on 1 January 2004 (or 1 January 2003 for women living in Amsterdam).Because of different HIV prevalences in region of origin (such as sub-Saharan Africa) also the risk of being diagnosed with HIV during the pregnancy is likely to differ according to region of origin. To analyse this for our cohort, we performed an additional analysis, in which the odds ratio (OR) for the risk of new HIV diagnosis during pregnancy was stratified for region of origin.
Results
As shown in tables 1 and 2, in total 481 women were found to be HIV-infected in pregnancy or were pregnant for the first time after an HIV diagnosis between 1 January 2000 and 1 January 2004. 33.7% of the cases were newly discovered infections. In the next period between 1 January 2004 and 1 January 2008, during which period all women were tested according to the opt-out principle, and 214 women tested positive in the first trimester of whom 80.3% were newly diagnosed and the remainder were pregnant for the first time after an HIV diagnosis.
The number of first pregnancies in HIV-infected pregnant women is smaller in the second period than in the period before the start of the national screening. The largest group of HIV-infected women in both periods, known to be infected or newly discovered during pregnancy originated from sub-Saharan Africa. The majority of women were infected by heterosexual contact. Of the women diagnosed with HIV before pregnancy, 68.1% initiated HAART before pregnancy. Unfortunately, data on the use of HAART was missing in more than 10% of the women.
The diagnosis of a previously unknown HIV infection during pregnancy was 8 times higher during the new non-selective screening strategy according the opt-out principle than in the period before (table 3) . Younger women and women originating from outside the Netherlands were more likely to be diagnosed with a previously unknown HIV infection during pregnancy. After stratifying the period into two periods: the selective national HIV pregnancy screening strategy (before 2004) and the non-selective strategy (2004 or later), it appeared that before the Effectiveness of Dutch antenatal HIV testingimplementation of the national screening diagnosis of a previously unknown HIV infection during pregnancy was more likely in younger women and in women originating from other countries than the Netherlands (table 4) .
However, after implementation of the national non-selective screening strategy, both age and origin were no longer significantly associated with the diagnosis of a previously unknown HIV infection during pregnancy. Factors that were included in the multivariate model were period new HIV diagnosis, region of origin and age at the start of pregnancy.
Table 2 HIV-infected pregnant women and children stratified to period
Before screening During screening 
Discussion
The present study shows that a national screening programme that includes non-selective antenatal testing on HIV according to the opt-out principle followed by an effective prophylaxis of mother-to-child transmission of HIV is an effective strategy to reduce perinatal HIV nfections. The number of HIV-infected children born in the Netherlands decreased dramatically. In the Netherlands, HAART is given to all pregnant women known to be HIV-infected from before the study period. In the present study, data on the use of HAART was missing in more than 10% of all women but because of the obligated referral of HIV-infected pregnant women to specific HIV-treating centres, likely most of the women were treated according to the Dutch consensus on treatment to prevent mother-tochild-transmission of HIV, i.e. to treat at the latest with HAART from 24 weeks onwards. 13 Since no child was infected born to HIV-infected women of whom the HIV infection was known before pregnancy or by first trimester screening, the prevention programme of mother-tochild-transmission of HIV appears effective. This is similar to data from other resource rich countries where HAART is used for prevention of mother-to-child-transmission. 14 Data on the national registration is not available to measure the uptake of testing because we only have access to data on HIV-infected women and children registered in the ATHENA observational study. From a study in the Amsterdam region, it appeared that the change of an opt-in policy to an opt-out policy in 2003 led to a decrease of declining the test from 13.6 to 1.4%. 8 In the Academic Medical Center in the same region, virtually all the pregnant women in the hospital and in the multicultural neighbourhood have been tested for HIV at first visit since 2004 (data from the local electronic patient database-not shown). Non-selective screening using opt-out has been implemented during the last years in many countries or states. 10, 11, [15] [16] [17] [18] A cross-sectional survey at 14 geographically diverse clinics in the United States showed that the large majority of women agree with and support HIV testing as a part of routine prenatal care. 19 Also, in the local experience of the largest HIV-centre in the Netherlands, the Academic medical centre in Amsterdam, women found to be HIV-infected by screening using the opt-out principle never complained about the way of testing but all were glad that they could make use of the prevention programme.
The national antenatal screening did not result in the discovery of more HIV infections than in the preceding years. Apart from the fact that the data of 2007 were still incomplete, three factors might be important to explain this unexpected finding. First, only first pregnancies in the ATHENA observational cohort are used for these tables. After the availability of HAART as treatment in general and as prophylaxis in pregnancy in particular, shortly before the first period in this study, women that did not dare to get pregnant before, started to get pregnant for the first time. Second, the number of pregnancies per year has declined gradually but substantially from 210.000 in 2000 to 181.000 in 2007 (À13%). 20 Third, there is a shift in the number of first HIV diagnoses between persons from different regions. If the data of the ATHENA observational cohort are treated in the same way as the data in the present study (with Amsterdam data of 2003 included in the second period), the number of newly diagnosed HIV-infected women from the Netherlands increased from 240 in the first period to 285 in the second period, but the women originating from sub-Saharan Africa decreased from 716 to 646 whereas the women from other countries rose from 328 to 349. This shift might be the result of the restricted governmental policy in the last period towards the uptake of immigrants in general but including many women from AIDS endemic areas. The increment of the population in the Netherlands in the second period was 147.367, which was 63% lower than in the first period (394.082). However, in spite of this decrease the proportion of women originating from not Western countries excluding Maroc and Turkey was 32% in the second as opposed to 44% in the first period. 20 Before the implementation of the national first trimester screening on HIV, in areas outside of Amsterdam only women at increased risk of an HIV infection were offered a test. The most obvious risk factors were origin from an AIDS endemic area and teenage pregnancies explaining that before the implementation of the national screening, diagnosis of a previously unknown HIV infection during pregnancy was more likely in younger women and in women originating from other countries than the Netherlands. After implementation of the national screening, it was to be expected that the chance of detection in pregnancy would mainly increase in women without obvious risk behaviour. Indeed the risk of detection by the antenatal screening of an HIV infection in Dutch women increased as compared with the first period, whereas the risk of detection in younger women and women originating from countries other than the Netherlands was no longer significantly associated with the detection of a previously unknown HIV infection in the pregnancy.
Despite the probably high uptake of the antenatal screening and the highly efficient prophylaxis of MTCT of HIV, infections did occur in women that tested negative in the first trimester. Similar data have been reported in the UK and Northern Alberta due to seroconversion of the pregnant (or lactating) women. 10, 21 HIV-seroconversions in pregnancy are not uncommon as shown in North Carolina. 22 This study and a recent study from South Africa indicated that the incidence of HIV infection is 4 times higher in pregnancy than outside of pregnancy. 22, 23 An infection can occur after the first trimester screening or can be missed by first trimester testing because of the window phase in an early infection. 22 Solutions to prevent such infections of children are usually sought in pooled testing of HIV-negatively tested specimen again by RNA-PCR to detect infections in the window phase or by testing pregnant women all or only those at risk again before labour by rapid HIV-testing. 22, 24 However, a better approach for all women would be testing of the partner together with the pregnant woman preferably extended by pooled HIV-RNA testing. Only if such combined testing fails or in case of late presentation of the pregnant woman rapid testing of the pregnant women before delivery seems prudent to start prophylaxis as soon as possible. It is time to discuss such a policy in order to make prevention of mother-to-child-transmission even more effective than nowadays and to start trying to protect women against infections by their partners. 25 Notwithstanding the limited number of vertical transmissions due to maternal infections after the first trimester screening, the present study clearly demonstrates the benefits of a nation-wide non-selective antenatal screening according to the opt-out principle in combination with a programme of effective prevention of mother-to-child transmission.
A national screening on HIV in pregnancy according to the opt-out principle virtually eliminated vertical transmission of HIV in women infected before pregnancy. First trimester HIV screening misses HIV infection of a mother during pregnancy or breast feeding and subsequent vertical transmission. Testing of the partner and/or retesting in late pregnancy should be considered to eliminate residual vertical transmission of HIV. In terms of identification of new HIV infections during pregnancy, the new screening programme is superior to the old programme of selective screening.
